Can Ozempic Fix Our Obesity Crisis?
![Can Ozempic Fix Our Obesity Crisis?](https://www.podcastworld.io/podcast-images/the-doctor-s-farmacy-with-mark-hyman-m-d-31xvsg8m.webp)
View the Show Notes For This Episode
Get Free Weekly Health Tips from Dr. Hyman
Sign Up for Dr. Hyman’s Weekly Longevity Journal
Get Ad-free Episodes & Dr. Hyman+ Audio Exclusives
Ozempic and other GLP-1 agonists like Wegovy have exploded as “miracle weight loss drugs.” But as the research unfolds, we’re quickly discovering that these drugs are not risk free and come with some very concerning side effects.
In today’s episode of my series I’m calling Health Bites, I dive deep into the complexities of Ozempic. From nationwide shortages, high costs, the lack of insurance coverage, and severe, somewhat common, side effects, I explore the hurdles of Ozempic and question if it's truly a sustainable solution to our growing obesity crisis.
This episode is brought to you by Mitopure and Cozy Earth.
Support essential mitochondrial health and save 10% on Mitopure. Visit TimelineNutrition.com/Drhyman and use code DRHYMAN10.
Right now, you can save 40% when you upgrade to Cozy Earth sheets. Just head over to CozyEarth.com and use code DRHYMAN.
Here are more details from the episode (audio version / Apple Subscriber version):
- Current and potential uses for Ozempic and GLP-1 (6:42 / 4:01)
- Common side effects from Ozempic (8:48 / 6:07)
- Understanding the obesity and chronic disease crisis (9:33 / 6:52)
- Long-term risks associated with Ozempic (14:47 / 12:06)
- Combatting the idea that obesity is genetic (17:54 / 15:13)
- Can you be healthy at any size? (20:37 / 17:55)
- How traditional medicine misses the mark in addressing obesity (24:36 / 21:55)
- Clinical research findings of Ozempic use (31:44 / 29:03)
- Addressing the root cause of obesity and type 2 diabetes (35:34 / 32:53)
Mentioned in this episode
Dr. Hyman’s Free Sleep Masterclass
Connect with Dr. Mark Hyman on Twitter, Instagram, Facebook, and YouTube
Hosted on Acast. See acast.com/privacy for more information.